REGN4659 / Regeneron, Sanofi - LARVOL DELTA

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - P1; N=17; Terminated; Sponsor: Regeneron Pharmaceuticals; N=134 ➔ 17; Trial completion date: Jun 2021 ➔ Dec 2019; Recruiting ➔ Terminated; Trial primary completion date: Jun 2021 ➔ Dec 2019; Program reprioritization

Clinical • Combination therapy • Enrollment change • Trial completion date • Trial primary completion date • Trial termination